BRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update
|
|
- Scarlett Dawson
- 6 years ago
- Views:
Transcription
1 BRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Table of Contents Data Supplement 1: Additional Evidence Table(s) Table 1: Characteristics of Studies Identified in the Search of the Literature Table 2: Study Quality Assessment Data Supplement 2: Search Strategy String and Dates Data Supplement 3: QUOROM Diagram Data Supplement 4: Clinical Questions Data Supplement 5: MCC table Data Supplement 6: Original recommendations compared with updated recommendations References
2 Data Supplement 1: Additional Evidence Table(s) Table 1: Characteristics of Studies Identified in the Search of the Literature Trial ID: RTOG 0232 NCT Number: Title: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma Randomized, open-label, phase III study Experimental agent: Interstitial brachytherapy only (iodine 125 and palladium 103 given as interstitial seeds) EBRT (3DCRT or IMRT) 5 days a week for 5 weeks + interstitial brachytherapy only (iodine 125 and palladium 103 given as interstitial seeds) Planned Enrollment: 588 Active, not recruiting Radiation Therapy Oncology Group Trial ID: ASCENDE-RT NCT Number: Title: A Randomized Phase III Study Comparing Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by High Dose 3-D Conformal Boost Versus Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by 125- Iodine Brachytherapy Implant Boost for Patients With Intermediate and High Risk Localized Prostate Cancer Randomized, open-label, phase III study Experimental agent: Androgen suppression, radiotherapy, iodine 125 brachytherapy Androgen suppression, radiotherapy Planned Enrollment: 400 Active, not recruiting University of British Columbia Trial ID: Hoskin et al, 2007 NCT Number: N/A Title: High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial Randomized phase III study Experimental agent: EBRT + HDR Brachytherapy EBRT Actual recruitment: 200 Closed UK Department of Health and Cancer Research UK Trial ID: Sathya et al, 2005 NCT Number: N/A Title: Randomized Trial Comparing Iridium Implant Plus External-Beam Radiation Therapy With External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate Randomized phase III study Experimental agent: EBRT + HDR Brachytherapy EBRT Actual recruitment: 104 Closed Ontario Clinical Oncology Group (OCOG) Trial ID: GMOR_HDR Monotherapy RCT NCT Number:
3 Title: A Randomized Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer Randomized, open-label, phase 2 study Experimental agent: HDR Brachytherapy 1 fraction HDR Brachytherapy 2 fractions Planned Enrollment: 174 Ongoing, not recruiting Sunnybrook Health Sciences Centre Table 2: Study Quality Assessment Author Year Reference Prestidge BR, RTOG [Abstract] Morris JW, ,3 ACENDE-RT Hoskin PJ, Sathya JR, Adequate Randomization Concealed Allocation Sufficient Sample Size Similar Groups Blinded Validated and Reliable Measures Adequate Followup Intention to Treat Analysis Insignificant COIs Overall Potential Risk of Bias a ? + Low Low +? + +? + + +? Low ? ? + Low Morton G, ? + Intermediate Note: +, indicates criteria was met; -, indicates criteria was not met;?, indicates insufficient detail, not reported, and/or uncertain if the criteria was met; NA, indicates not applicable. a Ratings are based on the estimation of whether the criterion was met and the extent of potential bias, not simply on reporting.
4 Data Supplement 2: Search Strategy String and Dates Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Sept > Search Strategy: (Cs-137 or 137-Cs or 137Cs or Cs137 or cesium-137 or 137-cesium or cesium137 or 137cesium).mp. (5178) 2 (Cs-131 or 131-Cs or 131Cs or Cs131 or cesium-131 or 131-cesium or cesium131 or 131cesium).mp. (175) 3 (I-125 or 125-I or 125I or I125 or iodine-125 or 125-iodine or iodine125 or 125iodine).mp. (52098) 4 (Pd-103 or 103-Pd or 103Pd or Pd103 or palladium-103 or 103-palladium or pallidum103 or 103palladium).mp. (659) 5 brachytherap$.mp. or brachytherapy/ (18878) 6 (internal radiotherap$ or sealed source radiotherap$ or ((permanent or seed) adj4 implant$) or curietherap$ or endocurietherap$).mp. (5235) 7 or/1-6 (77313) 8 exp prostate cancer/ (95786) 9 (prostat$ adj2 (cancer$ or neoplasm$ or adenocarcinom$ or carcinom$ or malign$ or tumo?r$)).mp. (116277) 10 8 or 9 (116277) 11 (case reports or comment or editorial or historical article or letter or news or newspaper article or patient education handout).pt. ( ) 12 (7 and 10) not 11 (4093) 13 limit 12 to (english language and humans and yr="2011 -Current") (815) 14 from 13 keep (815)
5 Data Supplement 3: QUOROM Diagram
6 Data Supplement 4: Clinical Questions 1. In patients with prostate cancer, what is the efficacy of brachytherapy alone for clinical outcomes compared with external beam radiation therapy (EBRT) alone, or radical prostatectomy alone? 2. In patients with prostate cancer, what is the efficacy of brachytherapy combined with EBRT for clinical outcomes compared with brachytherapy alone, EBRT alone, or radical prostatectomy alone? 3. Among the isotopes used for low dose rate brachytherapy (e.g. Iodine-125, Palladium- 103, and Cesium-137), which isotope maximizes clinical outcomes when used in patients with newly diagnosed prostate cancer?
7 Data Supplement 5: MCC table 10 Most Common Co-occurring Chronic Conditions among Male Medicare Beneficiaries with Prostate Cancer (N = 1,016,617 ), 2011 Beneficiaries less than 65 years (N =26,243 ) Beneficiaries 65 years and older (N =990,374) N % N % Prostate cancer prevalence 0.9 Prostate cancer prevalence 8.8 Top 10 co-morbidities Top 10 co-morbidities Hypertension 17, Hypertension 693, Hyperlipidemia 13, Hyperlipidemia 590, Diabetes 9, Ischemic heart disease 457, Ischemic heart disease 9, Anemia 337, Anemia 8, Diabetes 312, Arthritis 7, Arthritis 308, Chronic kidney disease 6, Chronic kidney disease 239, Depression 6, Cataract 235, COPD 4, Heart failure 203, Heart failure 4, COPD 145, Notes: Prepared by IPG/OIPDA on May 15, Citation: Unpublished data provided by the Office of Information Products and Data Analytics, Centers for Medicare & Medicaid Services, May 2013 Data Source: CMS administrative claims data, January December 2011, from the Chronic Condition Warehouse (CCW), ccwdata.org. Population: Male Medicare beneficiaries enrolled in fee-for-service (FFS) coverage of both Parts A and B for the entire year. Beneficiaries who were enrolled at any point during the year in a Medicare Advantage (MA) plan were excluded as were beneficiaries who first became eligible for Medicare after January of the calendar year. Beneficiaries who died during the year were included up to their date of death if they meet the other inclusion criteria. Beneficiaries less than 65 years of age are primarily receiving Medicare due to a disability. Chronic Condition Measures: For these tables, chronic conditions were identified through Medicare administrative claims. Medicare beneficiaries were considered to have a chronic condition if the CMS administrative data had a claim indicating that they were receiving a service or treatment for the specific condition. The data tables include information for beneficiaries with one of twenty-eight chronic conditions identified in the CCW. Detailed information on the identification of chronic conditions in the CCW is available at: The list of 28 conditions include: Acquired hypothyroidism, Acute myocardial infarction, Alzheimer's Disease (including related Disorders or senile dementia), Anemia, Asthma, Atrial fibrillation, Autism, Benign prostatic hyperplasia, Breast cancer, Colon cancer, Endometrial cancer, Lung cancer, Prostate cancer, Cataract, Chronic kidney disease, COPD, Depression, Diabetes, Glaucoma, Heart failure, Hip/pelvic fracture, Hypertension, Hyperlipidemia, Ischemic heart disease, Osteoporosis, Arthritis (OA and RA), Schizophrenia (and other psychotic disorders) and Stroke.
8 Data Supplement 6: Original recommendations compared with updated recommendations Original Recommendations For patients with newly diagnosed low-risk or intermediate-risk prostate cancer who require or choose active treatment, LDR-BT alone is a treatment option as an alternative to EBRT alone or RP alone I-125 and Pd-103 are each reasonable isotope options in patients with prostate cancer. No recommendation can be made for or against using Cs-131 or the combination of EBRT and LDR-BT in the target patient population Patients should be encouraged to participate in clinical trials to test novel or targeted approaches to this disease Updated recommendations For low-risk prostate cancer patients who require or choose active treatment low dose rate brachytherapy (LDR) alone, external beam radiotherapy (EBRT) alone or radical prostatectomy (RP) should be offered to eligible patients For intermediate-risk prostate cancer patients choosing external beam radiotherapy with or without androgen deprivation therapy (ADT), brachytherapy boost (LDR or high dose rate (HDR)) should be offered to eligible patients. For low-intermediate risk prostate cancer (Gleason 7, PSA < 10 ng/ml or Gleason 6, PSA ng/ml) LDR brachytherapy alone may be offered as monotherapy. For high-risk prostate cancer patients receiving EBRT and ADT, brachytherapy boost (LDR or HDR) should be offered to eligible patients I-125 and Pd-103 are each reasonable isotope options for patients receiving LDR brachytherapy; no recommendation can be made for or against using Cs-131 or HDR monotherapy Patients should be encouraged to participate in clinical trials to test novel or targeted approaches to this disease
9 References 1. Prestidge B, Winter K, Sanda M, et al: Initial Report of NRG Oncology/RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate-Risk Prostatic Carcinoma. International journal of radiation oncology, biology, physics 96:S4, Morris WJ, Tyldesley S, Pai HH, et al: ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. ASCO Meeting Abstracts 33:3, Morris WJ, Tyldesley S, Rodda S, et al: ASCENDE-RT: An Analysis of Survial Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose- Escalated External Beam Boost for High- And Intermediate-Risk Prostate Cancer. Int J Radiation Oncol Biol Physics Accepted, in press, Hoskin PJ, Motohashi K, Bownes P, et al: High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 84:114-20, Sathya JR, Davis IR, Julian JA, et al: Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in nodenegative locally advanced cancer of the prostate. J Clin Oncol 23:1192-9, Morton G, Chung HT, McGuffin M, et al: Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5 Gy. Radiotherapy and Oncology, 2016
Overview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationDoes RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia
Does RT favor RP in long term Quality of Life? Juanita Crook MD FRCPC Professor of Radiation Oncology University of British Columbia Disclosures Advisory Board/honoraria: Varian Advisory Board: Breast
More informationSection: Therapy Effective Date: October 15, 2016 Subsection: Therapy Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: September 2016 Page: 1 of 10 Description High-dose rate (HDR) temporary prostate brachytherapy is a technique of delivering a high-intensity radiation source directly to the prostate
More informationHigh-Dose Rate Temporary Prostate Brachytherapy. Original Policy Date
MP 8.01.15 High-Dose Rate Temporary Prostate Brachytherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return
More informationThe clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology description
In response to an enquiry from the Scottish Radiotherapy Advisory Group Number 37 June 2011 The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology
More informationMEDICAL POLICY SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER
MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationLDR Monotherapy vs. HDR Monotherapy
Abstract No. 1234 LDR Monotherapy vs. HDR Monotherapy Is it time for LDR to retire? Gerard Morton 2 LDR Seed Brachytherapy First 2000 LDR patients from BCCA Low and Intermediate Risk LDR Implant Morris
More informationProstate cancer remains the most
Current controversies in prostate brachytherapy for prostate cancer Ibrahim Abu-Gheida, MD; Christopher Fleming, MD; Paul Ramia, MD; Omar Mian, MD PhD; Rahul Tendulkar, MD; and Jay Ciezki, MD Prostate
More informationMedical Policy. MP High-Dose Rate Temporary Prostate Brachytherapy
Medical Policy MP 8.01.33 BCBSA Ref. Policy: 8.01.33 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Therapy Related Policies 7.01.79 Cryoablation of Prostate Cancer 8.01.10 Charged-Particle
More informationThe Spa Hotel, Tunbridge Wells Friday 23 rd March Platinum sponsor
The Spa Hotel, Tunbridge Wells Friday 23 rd March 2018 Platinum sponsor ADT in brachytherapy Adding efficacy or just toxicity C. Salembier Department of Radiotherapy-Oncology Europe Hospitals Brussels
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationPHPG. Utilization and Expenditure Analysis for Dually Eligible SoonerCare Members with Chronic Conditions
PHPG The Pacific Health Policy Group Utilization and Expenditure Analysis for Dually Eligible SoonerCare Members with Chronic Conditions Prepared for: State of Oklahoma Oklahoma Health Care Authority April
More informationMEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationHow can we best use HDR brachytherapy to escalate dose in intermediate and high risk disease? Gerard Morton Associate Professor
How can we best use HDR brachytherapy to escalate dose in intermediate and high risk disease? Gerard Morton Associate Professor Objectives Why should we escalate dose? What HDR dose and fractionation should
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More informationExternal Beam Radiotherapy for Prostate Cancer
External Beam Radiotherapy for Prostate Cancer Chomporn Sitathanee, Radiation Oncology Unit Ramathibodi Hospital, Mahidol University Roles of RT in prostate cancer Definitive RT; intact prostate Post radical
More informationPROSTATE CANCER BRACHYTHERAPY. Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College
PROSTATE CANCER BRACHYTHERAPY Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College Risk categorization Very Low Risk Low Risk Intermediate Risk High Risk
More informationor low dose rate (LDR), brachytherapy
High dose rate brachytherapy for prostate cancer: Current techniques and applications to varying disease presentations Daniel J. Krauss, MD High dose rate (HDR) brachytherapy has been an option for managing
More informationMP Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds
Medical Policy MP 8.01.14 BCBSA Ref. Policy: 8.01.14 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Therapy Related Policies 7.01.79 Cryoablation of Prostate Cancer 8.01.10 Charged-Particle
More informationDescription. Section: Therapy Effective Date: October 15, 2015 Subsection: Therapy Original Policy Date: December 7, 2011 Subject:
Last Review Status/Date: September 2015 Page: 1 of 14 Description High-dose rate (HDR) temporary prostate brachytherapy is a technique of delivering a high-intensity radiation source directly to the prostate
More informationHDR vs. LDR Is One Better Than The Other?
HDR vs. LDR Is One Better Than The Other? Daniel Fernandez, MD, PhD 11/3/2017 New Frontiers in Urologic Oncology Learning Objectives Indications for prostate brachytherapy Identify pros/cons of HDR vs
More informationHigh-Risk Prostate Cancer: Local Therapy Matters
prostate cancer High-Risk Prostate Cancer: Local Therapy Matters Adam L. Liss, MD, and Daniel A. Hamstra, MD, PhD The second in a series of two articles on radiation and prostate cancer. See the May issue
More informationAdvances in Treatment of Cancer by Brachytherapy in Kenya, in Particular, Prostate Cancer
Research Article imedpub Journals www.imedpub.com Journal Of Medical Physics And Applied Sciences ISSN 2574-285X DOI: 1.21767/2574-285X.12 Advances in Treatment of Cancer by Brachytherapy in Kenya, in
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationExternal Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
More informationBrachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds. Original Policy Date
MP 8.01.11 Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Revised
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationEmbracing Technology & Timing of Salvage Hormones
Embracing Technology & Timing of Salvage Hormones Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology Sunnybrook Health Sciences Centre University of Toronto Us Too, Brampton October
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationSRO Tutorial: Prostate Cancer Clinics
SRO Tutorial: Prostate Cancer Clinics May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible, and
More informationNew research in prostate brachytherapy
New research in prostate brachytherapy Dr Ann Henry Associate Professor in Clinical Oncology University of Leeds and Leeds Cancer Centre PIVOTAL boost opening 2017 To evaluate - The benefits of pelvic
More informationName of Policy: High-Dose Rate Temporary Prostate Brachytherapy
Name of Policy: High-Dose Rate Temporary Prostate Brachytherapy Policy #: 024 Latest Review Date: June 2014 Category: Therapy Policy Grade: C Background/Definitions: As a general rule, benefits are payable
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationHow ICD-10 Affects Radiation Oncology. Presented by, Lashelle Bolton CPC, COC, CPC-I, CPMA
How ICD-10 Affects Radiation Oncology Presented by, Lashelle Bolton CPC, COC, CPC-I, CPMA ICD-10 ICD-10-CM has added new challenges to the radiation oncology specialty. Approximately 220 ICD-9-CM codes
More informationTanaka et al. BMC Cancer (2017) 17:573 DOI /s
Tanaka et al. BMC Cancer (2017) 17:573 DOI 10.1186/s12885-017-3565-1 RESEARCH ARTICLE Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated
More informationThe benefit of a preplanning procedure - view from oncologist. Dorota Kazberuk November, 2014 Otwock
The benefit of a preplanning procedure - view from oncologist Dorota Kazberuk 21-22 November, 2014 Otwock Brachytherapy is supreme tool in prostate cancer management with a wide range of options in every
More informationValidating and Grouping Diagnosis
Validating and Grouping Diagnosis DataSci Consulting CMS SAS User Group Conference, 2007 Grouping Grouping Grouping Goals Cover basic concepts about diagnoses and codes Share some examples Provide useful,
More informationWould SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy?
Would SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy? Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan Disclosure
More informationTypes of Prostate Radiation Data Points # 16
Changes across time and geography in the use of prostate radiation technologies for newly diagnosed older cancer patients: 2006-2008 Types of Prostate Radiation Data Points # 16 Prostate cancer is the
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationErectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More information20 Prostate Cancer Dan Ash
20 Prostate Cancer Dan Ash 1 Introduction Prostate cancer is a disease of ageing men for which the aetiology remains unknown. The incidence rises up to 30 to 40% in men over 80. The symptoms of localised
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
More informationMedical Policy. MP Hydrogel Spacer use During Radiotherapy for Prostate Cancer
Medical Policy BCBSA Ref. Policy: 7.01.164 Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Surgery Related Policies 8.01.47 Intensity-Modulated Radiotherapy of the Prostate 9.01.502 Experimental
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationCurrent Status of Accelerated Partial Breast Irradiation. Julia White MD Professor, Radiation Oncology
Current Status of Accelerated Partial Breast Irradiation Julia White MD Professor, Radiation Oncology I have no disclosures relative to the presented material Agenda ABPI Timeline APBI by Method Clinical
More information3/22/2014. Goals of this Presentation: in 15 min & 5 min Q & A. Radiotherapy for. Localized Prostate Cancer: What is New in 2014?
3/22/ Goals of this Presentation: in 15 min & 5 min Q & A 1. Potency Preservation. a. Dosimetric considerations Radiotherapy for b. Drugs 2. Update on duration of short term ADT Mack III, MD Professor
More informationPROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER
PROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER Alberto Bossi Radiotherapy and Oncology Gustave Roussy, Villejuif, France PROSTATE CANCER, Radiotherapy IGRT RT + ADT: short vs
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationDOSIMETRIC OPTIONS AND POSSIBILITIES OF PROSTATE LDR BRACHYTHERAPY WITH PERMANENT I-125 IMPLANTS
DOSIMETRIC OPTIONS AND POSSIBILITIES OF PROSTATE LDR BRACHYTHERAPY WITH PERMANENT I-125 IMPLANTS Andrius IVANAUSKAS*, Eduardas ALEKNAVIČIUS*, Arvydas BURNECKIS*, Albert MILLER *Institute of Oncology Vilnius
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationActive surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation
Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation Alice Dragomir, PhD Fabio Cury, MD Armen Aprikian, MD Introduction Clinical and economic burden
More informationModern Dose Fractionation and Treatment Techniques for Definitive Prostate RT
Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Daniel J Bourgeois, III MD, MPH Board Certified Radiation Oncologist Southeast Louisiana Radiation Oncology Group (SLROG) Disclosures
More informationCyberKnife SBRT for Prostate Cancer
CyberKnife SBRT for Prostate Cancer Robert Meier, MD Swedish Radiosurgery Center Swedish Cancer Institute Seattle, WA 2017 ESTRO Meeting, Vienna Austria 5-year safety, efficacy & quality of life outcomes
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationThe Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation. Roberto Alonzi Mount Vernon Cancer Centre
The Paul Evans Memorial Lecture Functional radiotherapy targeting using focused dose escalation Roberto Alonzi Mount Vernon Cancer Centre Overview Introduction and rationale for focused dose escalation
More informationOral Communications. Prostata: Diagnosis and treatment of localized and locally advanced prostate cancer
Prostata: Diagnosis and treatment of localized and locally advanced prostate cancer Oral Communications Elisa Zanardi UOC Clinica di Oncologia Medica Ospedale Policlinico San Martino Dipartimento di Medicina
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS
More informationGYNECOLOGIC CANCER and RADIATION THERAPY. Jon Anders M.D. Radiation Oncology
GYNECOLOGIC CANCER and RADIATION THERAPY Jon Anders M.D. Radiation Oncology Brachytherapy Comes from the Greek brakhus meaning short Brachytherapy is treatment at short distance Intracavitary vs interstitial
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationHealthcare Professional Guide
Healthcare Professional Guide Brachytherapy: The precise answer for tackling prostate cancer Because life is for living Radiotherapy: a cornerstone of prostate cancer care Prostate cancer is the most commonly
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD, Mary J. Mackenzie, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
More informationRadiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK
Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary
More informationRadiation Dose Escalation for Localized Prostate Cancer
Radiation Dose Escalation for Localized Prostate Cancer Intensity-Modulated Radiotherapy Versus Permanent Transperineal Brachytherapy William W. Wong, MD 1 ; Sujay A. Vora, MD 1 ; Steven E. Schild, MD
More informationTrina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April
Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April 17, 2016 Discuss permanent prostate brachytherapy and
More informationTRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY
TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 1 TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY BRENDAN CAREY, MD TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 2 TRANSRECTAL ULTRASOUND-GUIDED
More informationProstate Cancer Treatment Decision Information Background
Prostate Cancer Treatment Decision Information Background A group of Radiotherapy Clinics of Georgia (RCOG) prostate cancer (PCa) patients developed this web site, in part, based on a slide presentation
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationdoi: /s (03) CLINICAL INVESTIGATION
doi:10.1016/s0360-3016(03)01746-2 Int. J. Radiation Oncology Biol. Phys., Vol. 58, No. 4, pp. 1048 1055, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More informationPCa Commentary. Seattle Prostate Institute CONTENTS. Volume 71 September-October 2011
Volume 71 September-October 2011 PCa Commentary CONTENTS PERMANENT SEED BRACHYTHERAPY FOR HIGH- RISK PROSTATE CANCER: 1 CABOZANTINIB: Startling Responses Reported at June ASCO Meeting in Metastatic Castrate
More informationOpen clinical uro-oncology trials in Canada
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES
More informationIQSS 2019 QCDR and MIPS Measure Specifications
IQSS1 Hypogonadism: Serum T, CBC, PSA, IPSS within 6 months of Rx Percentage of patients with a Effective Clinical Patients with documented new diagnosis of hypogonadism receiving androgen replacement
More informationUpdated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy for Locally and Locally Advanced
Clinical Urology High-Dose Rate Brachytherapy for Prostate Cancer International Braz J Urol Vol. 34 (3): 293-301, May - June, 2008 Updated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy
More informationImplementation Date: July 2014 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 10 Radiation Oncology Last Review Date: March 2014 Guideline Number: NIA_CG_124 Last Revised Date:
More informationAn Update on Radiation Therapy for Prostate Cancer
An Update on Radiation Therapy for Prostate Cancer David C. Beyer, MD, FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Objectives Review significant new data Identify leading trends in PCa
More informationTechnological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review
Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review Jayatissa R.M.G.C.S.B. (B.Sc.) Department of Radiography/Radiotherapy, Faculty of Allied Health
More informationHypofractionated Radiotherapy for breast cancer: Updated evidence
2 rd Bangladesh Breast Cancer Conference, Dhaka, December 2017 Hypofractionated Radiotherapy for breast cancer: Updated evidence Tabassum Wadasadawala Associate Professor of Radiation Oncology Tata Memorial
More informationProstate cancer: Update from the BCCA
Prostate cancer: Update from the BCCA Tom Pickles Clinical Professor, UBC Topics 1. Incidence & Utilization rates 2. New developments with External Beam RT IGRT, VMAT and other enhancements Optimizing
More informationProstate Cancer. 3DCRT vs IMRT : Hasan Murshed
Prostate Cancer 3DCRT vs IMRT : the second debate Hasan Murshed Take home message IMRT allows dose escalation. Preliminary data shows IMRT technique improves cancer control while keeping acceptable morbidity
More informationMeasure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (#625) Steward: Active Health Management
Measure Name: Prostate Cancer: Cancer Surveillance Owner: NQF (625) Measure Code: PRS Rule : Applicable Provider Specialty: General Criteria Summary Steward: Active Health Management Lab Data: Y Percentage
More informationThe Evolution of RT Techniques for Gynaecological Cancers in a developing country context
The Evolution of RT Techniques for Gynaecological Cancers in a developing country context Hannah Simonds Stellenbosch University/ Tygerberg Academic Hospital ESMO Africa 2017 I have no disclosures External
More informationCancer Endorsement Maintenance 2011-Maintenance Measures
Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationFriday 13th May The Roxburghe Hotel, Edinburgh. Abstracts
Friday 13th May 2016 The Roxburghe Hotel, Edinburgh Abstracts NOTES ABSTRACTS FOR PRESENTATION Abstract Title First Author Institution Abstract # Page ORAL & POSTER PRESENTATION PHYSICS ABSTRACTS MRI
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationEvaluation of Normal Tissue Complication Probability and Risk of Second Primary Cancer in Prostate Radiotherapy
Evaluation of Normal Tissue Complication Probability and Risk of Second Primary Cancer in Prostate Radiotherapy Rungdham Takam Thesis submitted for the degree of Doctor of Philosophy in The School of Chemistry
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED
More informationRadiotherapy Advances
Radiotherapy Advances Not Radiotherapy Principles IMRT IGRT Image Fusion Planning Introduction IMRT = Intensity Modulated RadioTherapy Restriction: IMRT with photon beams IMRT: Highly conformal technique
More informationRADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS
RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS HLC176A February 2015 Neha Maliwal Project Analyst ISBN: 1-62296-043-2 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More information